Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 286

1.

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H, Holman D, Keefer MC, Wolff M, Frey SE; NIAID HIV Vaccine Trials Network..

Vaccine. 2003 Jun 20;21(21-22):2933-47.

PMID:
12798637
2.

Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. NIAID AIDS Vaccine Clinical Trials Network.

Keefer MC, Belshe R, Graham B, McElrath J, Clements ML, Sposto R, Fast P.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S139-40. No abstract available.

PMID:
7865288
3.

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.

Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ.

AIDS. 1998 Dec 24;12(18):2407-15.

PMID:
9875578
4.

Safety profile of recombinant canarypox HIV vaccines.

de Bruyn G, Rossini AJ, Chiu YL, Holman D, Elizaga ML, Frey SE, Burke D, Evans TG, Corey L, Keefer MC.

Vaccine. 2004 Jan 26;22(5-6):704-13.

PMID:
14741163
5.

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.

Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, Verani-Ketter N, Erb S, Smith CM, Belshe RB, Wagner LJ, McElrath MJ, Schwartz DH, Fast P.

AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1163-77.

PMID:
9310283
6.
7.

Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.

Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, Metch BJ, Hansen M, Allen M, Cao H, Montefiori DC, Tomaras GD, Gurunathan S, Eastman DJ, do Lago RF, Jean S, Lama JR, Lawrence DN, Wright PF; 026 Protocol Team and the NIAID HIV Vaccine Trials Network..

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):222-30.

PMID:
17693888
9.

Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients.

Ackers ML, Parekh B, Evans TG, Berman P, Phillips S, Allen M, McDougal JS.

J Infect Dis. 2003 Mar 15;187(6):879-86. Epub 2003 Feb 27.

PMID:
12660933
10.

The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome research.

Fischer E, Rieux V, Guillet JG, Kazatchkine M.

Mem Inst Oswaldo Cruz. 2005 Feb;100(1):79-84. Epub 2005 Apr 12.

11.

Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefiori DC, Gorse GJ, Frey SE, Keefer MC, Evans TG, Dolin R, Schwartz DH, Harro C, Graham B, Spearman PW, Mulligan M, Goepfert P; AIDS Vaccine Evaluation Group..

J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):254-61.

PMID:
11873074
12.

Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.

Wright PF, Mestecky J, McElrath MJ, Keefer MC, Gorse GJ, Goepfert PA, Moldoveanu Z, Schwartz D, Spearman PW, El Habib R, Spring MD, Zhu Y, Smith C, Flores J, Weinhold KJ; National Institutes of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group..

J Infect Dis. 2004 Apr 1;189(7):1221-31. Epub 2004 Mar 15.

PMID:
15031791
13.

Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

Belshe RB, Stevens C, Gorse GJ, Buchbinder S, Weinhold K, Sheppard H, Stablein D, Self S, McNamara J, Frey S, Flores J, Excler JL, Klein M, Habib RE, Duliege AM, Harro C, Corey L, Keefer M, Mulligan M, Wright P, Celum C, Judson F, Mayer K, McKirnan D, Marmor M, Woody G; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET)..

J Infect Dis. 2001 May 1;183(9):1343-52. Epub 2001 Apr 10.

PMID:
11294665
14.

Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218).

Lambert JS, McNamara J, Katz SL, Fenton T, Kang M, VanCott TC, Livingston R, Hawkins E, Moye J Jr, Borkowsky W, Johnson D, Yogev R, Duliege AM, Francis D, Gershon A, Wara D, Martin N, Levin M, McSherry G, Smith G.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):451-61.

PMID:
9859958
15.
16.

HIV vaccines in infants and children.

Lambert JS.

Paediatr Drugs. 2005;7(5):267-76. Review.

PMID:
16220994
17.

MVA as a vector for vaccines against HIV-1.

Im EJ, Hanke T.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S89-97. Review.

PMID:
15285708
18.

Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults.

Durier C, Launay O, Meiffrédy V, Saïdi Y, Salmon D, Lévy Y, Guillet JG, Pialoux G, Aboulker JP.

AIDS. 2006 Apr 24;20(7):1039-49.

PMID:
16603857
19.

National vaccine effort seen as insufficient.

[No authors listed]

AIDS Alert. 1998 Jan;13(1):4-6.

PMID:
11364864
20.

[The quest for an HIV vaccine].

Girard MP.

Bull Acad Natl Med. 2005 May;189(5):831-44; discussion 844. Review. French.

PMID:
16433455

Supplemental Content

Support Center